UK markets close in 7 hours 38 minutes

Xvivo Perfusion AB (publ) (0RKL.L)

LSE - LSE Delayed price. Currency in SEK
Add to watchlist
357.50-16.33 (-4.37%)
As of 08:35AM BST. Market open.
Currency in SEK

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 2.09
52-week change 316.62%
S&P500 52-week change 322.64%
52-week high 3367.00
52-week low 3205.50
50-day moving average 3291.55
200-day moving average 3282.98

Share statistics

Avg vol (3-month) 39.84k
Avg vol (10-day) 34.45k
Shares outstanding 526.4M
Implied shares outstanding 6N/A
Float 825.26M
% held by insiders 110.61%
% held by institutions 158.26%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 15.37%
Operating margin (ttm)-9.58%

Management effectiveness

Return on assets (ttm)0.17%
Return on equity (ttm)5.44%

Income statement

Revenue (ttm)597.54M
Revenue per share (ttm)19.96
Quarterly revenue growth (yoy)18.40%
Gross profit (ttm)N/A
EBITDA 19.03M
Net income avi to common (ttm)91.82M
Diluted EPS (ttm)0.24
Quarterly earnings growth (yoy)9,228.90%

Balance sheet

Total cash (mrq)546.09M
Total cash per share (mrq)17.34
Total debt (mrq)31.44M
Total debt/equity (mrq)1.62%
Current ratio (mrq)6.14
Book value per share (mrq)61.75

Cash flow statement

Operating cash flow (ttm)46.29M
Levered free cash flow (ttm)-143.57M